However, Nurix believes its protein degraders are superior as they are orally available – thus providing systemic distribution – easily manufactured at scale, and (unlike CRISPR) reversible.

The strong performance of NX-5948 has bolstered confidence in Nurix's protein degradation platform. Analysts note that the early Progression-Free Survival (PFS) curves for BTK degraders appear ...

and a year earlier Gilead Sciences forged a $2.3 billion alliance with Nurix on degraders for oncology indications, with a $45 million upfront fee. Jazz has reached an agreement to buy Chimerix ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B ...

Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...